BioSpace News Archive

Madrigal Pharmaceuticals, Inc. today announced that Ronald Filippo has been appointed Chief Information Officer.

Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a peer-reviewed publication describing the safety, tolerability, pharmacokinetic and clinical efficacy results for the NX-13 Phase 1b trial in patients with ulcerative colitis (UC) in the Journal of Crohn’s and Colitis.

Supira Medical, Inc. , a Shifamed portfolio company, announced today that it has received U.S. Food and Drug Administration (FDA) breakthrough device designation for its Supira System, a next-generation percutaneous ventricular assist device (pVAD).

ESSA Pharma Inc. today announced that the Company will be presenting at the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 12:00 p.m. ET in New York.

Xspray Pharma AB announced that XS003, its amorphous, non-crystalline formulation of nilotinib, has demonstrated bioavailability within the 80-125% range to TASIGNA® following oral administration with significantly lower dose.

Cyclo Therapeutics, Inc. today announced its abstract has been accepted for platform presentation at the 20th Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA.

CytoDyn Inc., a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced the appointment of Dr. Jacob Lalezari as interim CEO, effective November 17, 2023.

ABVC BioPharma, Inc. announced that it received a U.S. patent, Application No. 17/120,965, for the use of PDC-1421, a Radix Polygala extract, which is used in the Company’s asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder.

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems, announced that a global leader in animal health selected ValGenesis VLMS to digitize its corporate validation process.

Ainos, Inc. announced that positive top-line data has been reported from three clinical studies for its VELDONA® low-dose oral interferon formulation as a potential treatment for oral warts in HIV-seropositive patients.